Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Nonobese Patients With Enterobacteriaceae Bloodstream Infections.
Melissa SantibañezKristen BunnellAmanda HarringtonSusan BleasdaleEric WenzlerPublished in: Open forum infectious diseases (2019)
Neither predicted PK/PD parameters nor clinical outcomes differed significantly between obese and nonobese patients treated with piperacillin-tazobactam or cefepime. As the majority of patients received extended-infusion piperacillin-tazobactam for bacteremia due to pathogens with low MICs, the potentially detrimental pathophysiologic derangements caused by obesity may not have been realized. Further studies are warranted to establish the optimal treatment of serious infections in obese patients.
Keyphrases
- obese patients
- bariatric surgery
- weight loss
- gram negative
- metabolic syndrome
- roux en y gastric bypass
- gastric bypass
- multidrug resistant
- end stage renal disease
- adipose tissue
- type diabetes
- newly diagnosed
- ejection fraction
- insulin resistance
- chronic kidney disease
- low dose
- pseudomonas aeruginosa
- patient reported outcomes
- weight gain
- skeletal muscle
- klebsiella pneumoniae
- escherichia coli
- high fat diet induced
- physical activity
- urinary tract infection
- replacement therapy